Sophie L St Clair, Anthony G B Walters, Caroline A Crowther, Stuart R Dalziel, Carl Eagleton, Gregory D Gamble, Christopher J D McKinlay, Barry J Milne, Jane E Harding
{"title":"产前使用皮质类固醇后的生殖效果:奥克兰类固醇随机试验 50 年随访的二次分析。","authors":"Sophie L St Clair, Anthony G B Walters, Caroline A Crowther, Stuart R Dalziel, Carl Eagleton, Gregory D Gamble, Christopher J D McKinlay, Barry J Milne, Jane E Harding","doi":"10.1111/aogs.14984","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Antenatal corticosteroids are widely used to prevent morbidity and mortality after preterm birth, but there are ongoing concerns about the possible risk of long-term adverse effects, including perturbation of endocrine systems, with potential implications for reproduction. A small number of animal studies have suggested possible adverse effects on reproduction after antenatal exposure to corticosteroids, but there is a paucity of human data.</p><p><strong>Material and methods: </strong>This is a secondary cohort analysis of the 50-year follow-up of the Auckland Steroid Trial (1969-1974) comparing antenatal exposure to corticosteroids or placebo. Participants whose mothers took part in the placebo-controlled randomized trial of antenatal corticosteroids completed a questionnaire reporting reproductive outcomes at 50 years of age. The main outcome was at least one pregnancy ≥20 weeks or fathered at least one pregnancy ≥20 weeks. Additional outcomes included a number of pregnancies or fathered pregnancies ≥20 weeks, outcomes relating to female reproductive lifespan (including age at menarche and menopause), and outcomes relating to their offspring (including birthweight and gestation).</p><p><strong>Results: </strong>Of 917 eligible participants, 415 (45% of eligible) completed the questionnaire at a mean (SD) age of 49.3 (1.0) years. The proportion of participants who had experienced at least one pregnancy ≥20 weeks or fathered at least one pregnancy ≥20 weeks was similar in betamethasone and placebo-exposed groups (163/217 [75%] vs. 136/190 [72%]; RR 1.08, (95% CI 0.95 to 1.22); p = 0.23). Participants exposed to betamethasone had a slightly higher number of pregnancies or fathered pregnancies ≥20 weeks compared to those exposed to placebo (mean 1.89 vs. 1.60; marginal mean difference 0.20, (95% CI 0.03-0.37); p = 0.03). Other outcomes, including female reproductive lifespan and offspring-related outcomes, were similar in both randomized groups. There were also no differences in any outcomes between those born preterm and those born at term.</p><p><strong>Conclusions: </strong>Antenatal exposure to corticosteroids appears to have no clinically important effect on reproductive outcomes to 50 years.</p>","PeriodicalId":6990,"journal":{"name":"Acta Obstetricia et Gynecologica Scandinavica","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reproductive outcomes after antenatal corticosteroids: Secondary analysis of 50-year follow-up of the Auckland steroid randomized trial.\",\"authors\":\"Sophie L St Clair, Anthony G B Walters, Caroline A Crowther, Stuart R Dalziel, Carl Eagleton, Gregory D Gamble, Christopher J D McKinlay, Barry J Milne, Jane E Harding\",\"doi\":\"10.1111/aogs.14984\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Antenatal corticosteroids are widely used to prevent morbidity and mortality after preterm birth, but there are ongoing concerns about the possible risk of long-term adverse effects, including perturbation of endocrine systems, with potential implications for reproduction. A small number of animal studies have suggested possible adverse effects on reproduction after antenatal exposure to corticosteroids, but there is a paucity of human data.</p><p><strong>Material and methods: </strong>This is a secondary cohort analysis of the 50-year follow-up of the Auckland Steroid Trial (1969-1974) comparing antenatal exposure to corticosteroids or placebo. Participants whose mothers took part in the placebo-controlled randomized trial of antenatal corticosteroids completed a questionnaire reporting reproductive outcomes at 50 years of age. The main outcome was at least one pregnancy ≥20 weeks or fathered at least one pregnancy ≥20 weeks. Additional outcomes included a number of pregnancies or fathered pregnancies ≥20 weeks, outcomes relating to female reproductive lifespan (including age at menarche and menopause), and outcomes relating to their offspring (including birthweight and gestation).</p><p><strong>Results: </strong>Of 917 eligible participants, 415 (45% of eligible) completed the questionnaire at a mean (SD) age of 49.3 (1.0) years. The proportion of participants who had experienced at least one pregnancy ≥20 weeks or fathered at least one pregnancy ≥20 weeks was similar in betamethasone and placebo-exposed groups (163/217 [75%] vs. 136/190 [72%]; RR 1.08, (95% CI 0.95 to 1.22); p = 0.23). Participants exposed to betamethasone had a slightly higher number of pregnancies or fathered pregnancies ≥20 weeks compared to those exposed to placebo (mean 1.89 vs. 1.60; marginal mean difference 0.20, (95% CI 0.03-0.37); p = 0.03). Other outcomes, including female reproductive lifespan and offspring-related outcomes, were similar in both randomized groups. There were also no differences in any outcomes between those born preterm and those born at term.</p><p><strong>Conclusions: </strong>Antenatal exposure to corticosteroids appears to have no clinically important effect on reproductive outcomes to 50 years.</p>\",\"PeriodicalId\":6990,\"journal\":{\"name\":\"Acta Obstetricia et Gynecologica Scandinavica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Obstetricia et Gynecologica Scandinavica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/aogs.14984\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Obstetricia et Gynecologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/aogs.14984","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
导言:产前皮质类固醇被广泛用于预防早产后的发病率和死亡率,但人们一直担心其可能存在长期不良影响的风险,包括扰乱内分泌系统,对生殖系统造成潜在影响。少量动物实验表明,产前接触皮质类固醇可能会对生殖系统产生不良影响,但人类数据却很少:这是对奥克兰类固醇试验(1969-1974 年)50 年跟踪调查的二次队列分析,比较了产前接触皮质类固醇或安慰剂的情况。母亲参加了安慰剂对照随机产前皮质类固醇试验的参与者填写了一份问卷,报告了 50 岁时的生殖结果。主要结果是至少有一次怀孕时间≥20 周或至少有一次怀孕时间≥20 周的父亲。其他结果包括怀孕次数或父亲怀孕次数≥20 周、与女性生殖寿命有关的结果(包括初潮年龄和绝经年龄)以及与她们的后代有关的结果(包括出生体重和妊娠期):在 917 名符合条件的参与者中,有 415 人(占符合条件者的 45%)完成了问卷调查,她们的平均年龄(标准差)为 49.3 (1.0)岁。至少有一次妊娠≥20周或至少有一次妊娠≥20周的父亲的参与者比例在倍他米松组和安慰剂暴露组相似(163/217 [75%] vs. 136/190 [72%];RR 1.08,(95% CI 0.95至1.22);P = 0.23)。与使用安慰剂的参与者相比,使用倍他米松的参与者怀孕或妊娠≥20周的父亲人数略高(平均为1.89对1.60;边际平均差为0.20,(95% CI 0.03-0.37);P = 0.03)。其他结果,包括女性生殖寿命和后代相关结果,在两个随机分组中相似。早产儿和足月儿的任何结果也没有差异:结论:产前暴露于皮质类固醇似乎对50岁前的生殖结局没有临床重要影响。
Reproductive outcomes after antenatal corticosteroids: Secondary analysis of 50-year follow-up of the Auckland steroid randomized trial.
Introduction: Antenatal corticosteroids are widely used to prevent morbidity and mortality after preterm birth, but there are ongoing concerns about the possible risk of long-term adverse effects, including perturbation of endocrine systems, with potential implications for reproduction. A small number of animal studies have suggested possible adverse effects on reproduction after antenatal exposure to corticosteroids, but there is a paucity of human data.
Material and methods: This is a secondary cohort analysis of the 50-year follow-up of the Auckland Steroid Trial (1969-1974) comparing antenatal exposure to corticosteroids or placebo. Participants whose mothers took part in the placebo-controlled randomized trial of antenatal corticosteroids completed a questionnaire reporting reproductive outcomes at 50 years of age. The main outcome was at least one pregnancy ≥20 weeks or fathered at least one pregnancy ≥20 weeks. Additional outcomes included a number of pregnancies or fathered pregnancies ≥20 weeks, outcomes relating to female reproductive lifespan (including age at menarche and menopause), and outcomes relating to their offspring (including birthweight and gestation).
Results: Of 917 eligible participants, 415 (45% of eligible) completed the questionnaire at a mean (SD) age of 49.3 (1.0) years. The proportion of participants who had experienced at least one pregnancy ≥20 weeks or fathered at least one pregnancy ≥20 weeks was similar in betamethasone and placebo-exposed groups (163/217 [75%] vs. 136/190 [72%]; RR 1.08, (95% CI 0.95 to 1.22); p = 0.23). Participants exposed to betamethasone had a slightly higher number of pregnancies or fathered pregnancies ≥20 weeks compared to those exposed to placebo (mean 1.89 vs. 1.60; marginal mean difference 0.20, (95% CI 0.03-0.37); p = 0.03). Other outcomes, including female reproductive lifespan and offspring-related outcomes, were similar in both randomized groups. There were also no differences in any outcomes between those born preterm and those born at term.
Conclusions: Antenatal exposure to corticosteroids appears to have no clinically important effect on reproductive outcomes to 50 years.
期刊介绍:
Published monthly, Acta Obstetricia et Gynecologica Scandinavica is an international journal dedicated to providing the very latest information on the results of both clinical, basic and translational research work related to all aspects of women’s health from around the globe. The journal regularly publishes commentaries, reviews, and original articles on a wide variety of topics including: gynecology, pregnancy, birth, female urology, gynecologic oncology, fertility and reproductive biology.